Home Forums |
|
MDS Myelodysplastic syndromes |
|
Thread Tools | Search this Thread |
#1
|
|||
|
|||
Telintra-Revlimid Combo May Help Lower-Risk MDS Patients
From the MDS Beacon...
Telintra-Revlimid Combination May Be Effective And Safe In Lower-Risk MDS Patients by Jessica Langholtz Results from a Phase 1 clinical trial suggest that the combination of Telintra and Revlimid may be effective and safe in lower-risk myelodysplastic syndromes patients. The study investigators found that the combination of Telintra and Revlimid promoted the growth of new blood cells. In addition, several patients who were previously dependent on red blood cell transfusions became transfusion-independent after therapy. For the rest, see the article at MDS Beacon. |
#2
|
|||
|
|||
Here's the related eligible terms to participate in future upcoming clinical trials...
"Ages Eligible for Study:18 Years and older Genders Eligible for Study:Both Accepts Healthy Volunteers:no Criteria: Inclusion Criteria: - Histologic diagnosis of primary or de novo MDS using WHO classification - Non-del(5q) low or Intermediate-1risk MDS - ECOG performance status of 0-1 - Documented significant cytopenia for at least 2 months - Must have discontinued growth factors (EPO, G-CSF, GM-CSF) for at least 21 days prior to study entry - All study participants must be registered into the mandatory RevAssist® program and be willing and able to comply with the requirements of RevAssist® - Females of childbearing potential should have two negative serum pregnancy tests with a sensitivity of at least 50 mIU/mL. The first test should be performed within 10-14 days, and the second test within 24 hours of prescribing lenalidomide (prescriptions must be filled within seven days) Exclusion Criteria: - Known hypersensitivity to Telintra™ (intravenous or oral) - Known prior therapy with or hypersensitivity to thalidomide or lenalidomide - Prior allogenic bone marrow transplant for MDS - History or prior malignancy - Except for treated carcinoma of uterine cervix, basal cell or squamous cell skin cancer, or other cancers (e.g. breast, prostate) for which patient has been disease-free for at least 3 years. - MDS evolving from: - A pre-existing myeloproliferative disorder - An autoimmune disease - Secondary to prior treatment with radiation or chemotherapy - History of MDS IPSS score>1.0 - Pregnant or lactating women - Leptomeningeal or leukemic meningitis - Prior treatment with DNA methyltransferase inhibitors (DMTI) [e.g., azacitadine, decitabine, etc.]"
__________________
Ric: Low-risk MDS (blasts <4%); 4 cycles Revlimid no positive response; PRBC transfusion dependent; so far, 392'units' over 8 3/4 years; BMB #4 (15/04/01) shows evolution to AML (blasts 20-30%) 47,XY,del(5) (q22q35),+21[24][cp24]/46,XY(1). |
Thread Tools | Search this Thread |
|
|
Similar Threads | ||||
Thread | Thread Starter | Forum | Replies | Last Post |
Revlimid and High Risk MDS RAEB 2 - 18% Blasts | Peachy | MDS | 21 | Tue Mar 17, 2015 02:42 PM |
Thalidomide-Trisenox Combo for MDS Patients | Sally C | MDS | 0 | Wed May 16, 2012 04:32 PM |
The lower risk MDS patient at risk of rapid progression | akita | MDS | 0 | Mon Dec 27, 2010 04:28 AM |
New Oral Medication Gives Hope to Patients with Blood Cancer | Doug Mylie | Canada | 0 | Sat Mar 8, 2008 12:27 PM |